DOI:
10.1055/s-00000031
Klinische Monatsblätter für Augenheilkunde
LinksClose Window
References
Bock F, Onderka J, Dietrich T. et al.
Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.
Invest Ophthalmol Vis Sci 2007;
48: 2545-2552
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.